Boehringer Ingelheim GmbH, of Ingelheim, Germany, said that the review process for the marketing authorization application for Striverdi Respimat in the European Union had been completed successfully. The drug is indicated for patients with chronic obstructive pulmonary disease. Now that the review is complete, the company said that further national approvals in EU and European Economic Area countries will follow in due course.

• Merck Serono SA, of Rockland, Mass., part of Merck KGaA, said the FDA granted approval to its subsidiary, EMD Serono, Inc., for Gonal-f RFF Redi-ject (follitropin alfa injection), a disposable pre-filled drug injector pen intended for the subcutaneous injection of a liquid formulation of Gonal-f RFF. Gonal-f RFF Redi-ject is part of a global family of prefilled pens designed for patient self-administration of Gonal-f with demonstrated dose accuracy and designed with physicians and patients in mind. Gonal-f is prescribed to supplement or replace naturally occurring follicle-stimulating hormone, an essential hormone to treat infertility.

Valeant Pharmaceuticals International Inc., of Laval, Quebec, has been ordered by an arbitrator to make a one-time payment of $100 million in damages plus costs and fees to Anacor Pharmaceuticals Inc., of Palo Alto, Calif., to resolve a breach of contract dispute derived from services provided by Dow Pharmaceutical Sciences Inc. before it was acquired by Valeant. The order does not prevent the launch of Jublia (efinaconazole 10 percent topical solution). Anacor previously sought an award of at least $215 million plus injunctive relief.